Literature DB >> 32917781

Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?

Deborah M Stephens1, Heiko Schoder, Hongli Li, Jonathan Friedberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32917781      PMCID： PMC9364892          DOI： 10.2967/jnumed.120.242685

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  3 in total

1.  Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?

Authors:  Charles Mesguich; Krimo Bouabdallah; Laurence Bordenave; Noël Milpied; Elif Hindié
Journal:  J Nucl Med       Date:  2020-02-14       Impact factor: 10.057

2.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Authors:  Oliver W Press; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Erik S Mittra; Ann S LaCasce; John W Sweetenham; Paul M Barr; Michelle A Fanale; Michael V Knopp; Ariela Noy; Eric D Hsi; James R Cook; Mary Jo Lechowicz; Randy D Gascoyne; John P Leonard; Brad S Kahl; Bruce D Cheson; Richard I Fisher; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

3.  Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.

Authors:  Deborah M Stephens; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Ann S LaCasce; Paul M Barr; Michael V Knopp; Eric D Hsi; John P Leonard; Brad S Kahl; Sonali M Smith; Jonathan W Friedberg
Journal:  Blood       Date:  2019-10-10       Impact factor: 25.476
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.